We are live on ! Find out more
TS

Thomas Steyer Farallon Capital Management

AUM $21.7B
1-Year Est. Return 79.24%
 

Thomas Steyer founded Farallon Capital Management, a pioneering multi-strategy firm spanning credit, equities, real estate, and event-driven investing. Farallon became known for rigorous research and opportunistic capital allocation across cycles. Although Steyer later focused on public advocacy, the Farallon name remains important in hedge fund history and ongoing 13F tracking.

This Fund
S&P 500
This Quarter Est. Return
-2.9%
1 Year Est. Return
+79.24%
3 Year Est. Return
+204.51%
5 Year Est. Return
+270.91%
10 Year Est. Return
+1,884.18%
AUM
$13.2B
AUM Growth
-$2.13B
Cap. Flow
+$212M
Cap. Flow %
1.6%
Top 10 Hldgs %
51.27%
Holding
122
New
17
Increased
44
Reduced
28
Closed
23

Top Buys

Rank Stock Value
1
AGN
Allergan plc
AGN
+$853M
2
BRMK
Broadmark Realty Capital Inc. Common Stock
BRMK
+$778M
3
AABA
Altaba Inc
AABA
+$385M
4
PPLI
People Inc
PPLI
+$348M
5
BABA icon
Alibaba
BABA
+$288M

Top Sells

Rank Stock Value
1
RHT
Red Hat Inc
RHT
+$964M
2
APC
Anadarko Petroleum
APC
+$738M
3
ARRY
Array Biopharma Inc
ARRY
+$394M
4
BKNG icon
Booking.com
BKNG
+$128M
5
EFX icon
Equifax
EFX
+$117M

Sector Composition

Rank Sector Weight
1 Healthcare 45.06%
2 Technology 13.07%
3 Communication Services 12.09%
4 Industrials 6.1%
5 Consumer Discretionary 5.81%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RETA
76
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$14.6M 0.11%
182,060
-617,940
-77% -$52.4M
MLNX
77
DELISTED
Mellanox Technologies, Ltd.
MLNX
$13.7M 0.1%
+125,000
New +$13.8M
CCXI
78
DELISTED
ChemoCentryx, Inc.
CCXI
$13.7M 0.1%
2,013,396
+13,396
+0.7% +$101K
QTNT
79
DELISTED
Quotient Limited Ordinary Shares
QTNT
$13.2M 0.1%
42,500
-20,000
-32% -$7.71M
ACAD icon
80
Acadia Pharmaceuticals
ACAD
$5.08B
$12.6M 0.1%
+350,000
New +$10.6M
EIGR
81
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
$11.5M 0.09%
37,500
+4,167
+13% +$1.35M
SVRA icon
82
Savara
SVRA
$1.15B
$9.3M 0.07%
3,510,787
+35,787
+1% +$89.4K
AXSM icon
83
Axsome Therapeutics
AXSM
$10.9B
$8.1M 0.06%
+400,000
New +$10.3M
XGN icon
84
Exagen
XGN
$192M
$5.63M 0.04%
+363,336
New +$5.87M
PFNX
85
DELISTED
Pfenex Inc.
PFNX
$5.06M 0.04%
600,000
– –
CYCN icon
86
Cyclerion Therapeutics
CYCN
$18.2M
$4.57M 0.03%
18,831
-8,373
-31% -$1.81M
QURE icon
87
uniQure
QURE
$3.36B
$3.97M 0.03%
100,922
+922
+0.9% +$53.2K
GCVRZ
88
DELISTED
Sanofi Contingent Value Rights
GCVRZ
$3.89M 0.03%
6,827,805
– –
DMTK
89
DELISTED
DermTech, Inc. Common Stock
DMTK
$3.45M 0.03%
+615,385
New +$7.34M
PHAS
90
DELISTED
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
$3.37M 0.03%
807,928
+50,967
+7% +$406K
APTX
91
DELISTED
Aptinyx Inc. Common Stock
APTX
$2.35M 0.02%
674,141
+4,141
+0.6% +$14.9K
GOSS icon
92
Gossamer Bio
GOSS
$75.6M
$1.69M 0.01%
100,712
+712
+0.7% +$14.2K
COHR icon
93
Coherent
COHR
$56.7B
$1.68M 0.01%
+47,687
New +$1.82M
LRMR icon
94
Larimar Therapeutics
LRMR
$434M
$1.34M 0.01%
150,697
+697
+0.5% +$7.64K
ADPT icon
95
Adaptive Biotechnologies
ADPT
$4.15B
– –
-25,000
Closed -$1.21M
AKRO
96
DELISTED
Akero Therapeutics
AKRO
– –
-150,000
Closed -$2.87M
ASMB icon
97
Assembly Biosciences
ASMB
$700M
– –
-8,333
Closed -$1.35M
CDXS icon
98
Codexis
CDXS
$183M
– –
-1,250,000
Closed -$23M
FOX icon
99
Fox Class B
FOX
$25.6B
– –
-1,182,500
Closed -$43.2M
FOXA icon
100
Fox Class A
FOXA
$28.8B
– –
-836,400
Closed -$30.6M
1 2 3
4
5

Similar funds

BG
Bahl & Gaynor Cincinnati, Ohio $21.7B AUM 30.58% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $21.7B AUM 41.93% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $21.6B AUM 28.31% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $21.5B AUM 23.65% 1-Year Est. Return
CHP
Castle Hook Partners New York $21.8B AUM 215.45% 1-Year Est. Return
PAG
Private Advisor Group Morristown, New Jersey $21.8B AUM 28.57% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return

Thomas Steyer's Q3 2019 Portfolio in Review

As of Q3 2019, Thomas Steyer held 122 positions worth $13.2B, down 14% from $15.4B the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Thomas Steyer's Q3 2019 filing shows 17 new, 44 increased, 28 reduced and 23 closed positions. Its largest new stake was Broadmark Realty Capital Inc. Common Stock: 75,000,000 shares worth $77.3M. The largest sale was Red Hat Inc, an estimated $964M.

By sector, the portfolio is most concentrated in Healthcare at 45% of assets, up from 38% a quarter earlier, followed by Technology and Communication Services.

  • Thomas Steyer's largest Q3 2019 buy was Broadmark Realty Capital Inc. Common Stock: 75,000,000 shares worth $77.3M.
  • Thomas Steyer added most to Allergan plc in Q3 2019, an estimated $853M increase.
  • Thomas Steyer's biggest Q3 2019 reduction was Booking.com, cutting an estimated $128M.
  • Thomas Steyer fully exited Red Hat Inc in Q3 2019, selling an estimated $964M.
  • Thomas Steyer's ten largest holdings make up 51% of its $13.2B portfolio in Q3 2019.
  • Thomas Steyer opened 17 new positions and closed 23 in Q3 2019.
  • Thomas Steyer's portfolio value fell 14% quarter-over-quarter to $13.2B.

Based on Farallon Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.